As of May 26
| -0.10 / -2.94%|
The 2 analysts offering 12-month price forecasts for Merrimack Pharmaceuticals Inc have a median target of 9.00, with a high estimate of 15.00 and a low estimate of 3.00. The median estimate represents a +172.73% increase from the last price of 3.30.
The current consensus among 4 polled investment analysts is to Hold stock in Merrimack Pharmaceuticals Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.